Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Closer Look: Ambrx Doubles Down In China With Hisun Deal

This article was originally published in PharmAsia News

Executive Summary

San Diego-based Ambrx is aggressively striking deals with companies in China. PharmAsia News takes a closer look at a recent deal with Hisun and adds background to its growing ties to Big Pharma.

You may also be interested in...



Merck, Ambrx Partner In Effort To Create Better-Targeted Drug Conjugates

Unlike most work in antibody-drug conjugates, however, the collaboration will not focus on oncology but on a broad array of undisclosed targets that may be applicable in a wide variety of indications.

Bristol And Ambrx To Collaborate On Preclinical Assets For Type 2 Diabetes, Heart Failure

Bristol's second "String of Pearls" transaction in as many days includes a $24 million upfront payment to privately held Ambrx.

CROs at risk from China's new inventor regulation?

China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.

Topics

Related Companies

UsernamePublicRestriction

Register

CO180755

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel